- 2023.03.31
As a global innovative biotech company, we are passionate about creating transformational therapies through innovation to address unmet medical needs in oncology for patients worldwide.
Lemzoparlimab CD47
Uliledlimab CD73
Givastomig Claudin 18.2 x 4-1BB
TJ-L14B PD-L1 x 4 -1BB
mRNA, Probody
AI Design, Alphabody
Lemzoparlimab CD47
Uliledlimab CD73
Givastomig Claudin 18.2 x 4-1BB
TJ-L14B PD-L1 x 4 -1BB
mRNA, Probody
AI Design, Alphabody
Press Releases
2023.03.20
The Company announced date of reporting financial results for year 2022.
2023.03.13
I-Mab today issued a statement on the recent developments of the SVB.
2023.03.07
I-Mab has been granted “A” rating by Morgan Stanley Capital International ESG.
Events
I-Mab was established in June 2016
I-Mab completed Series A financing, raising $58 million
Third Venture Biopharma and Tasgen merged to form I-Mab, raising $120 million in Series B Financing
I-Mab successfully raised $227 million in Series C Financing
I-Mab was listed on the Nasdaq Global Market as a clinical-stage biotech company
I-Mab and AbbVie enter into global strategic partnership on development and commercialization of I-Mab's novel CD47 monoclonal antibody lemzoparlimab
I-Mab entered into $523 million private placement agreement with Hillhouse Capital-led consortium
I-Mab established its global footprint with 9 locations, including new R&D site in San Diego, and new GMP facility in Hangzhou
I-Mab and Jumpcan entered into a strategic partnership for commercialization of I-Mab’s highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa in mainland China
“Clinical researchers are real life superheroes providing innovative treatments to those in need.”
“I'm inspired by my colleagues' dedication to excellence in the work that we do; their kindness and care make it easy to work together on challenging projects.”
“At I-Mab, gender inclusivity is not a tagline. The Company provides various platforms for female employees to flourish. We feel much supported in our personal and career development.”
Since its establishment, I-Mab has been focusing on developing innovative biologics in immuno-oncology. Through three waves of innovation, we have built a globally competitive pipeline. Our global clinical development and strategic partnership model fuels our sustainable innovation and growth, with proven track record of validation and recognition.
Jingwu Zang
Founder and Chairman